NasdaqGS:BIIBBiotechs
Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval
Biogen (BIIB) has come back into focus after the European Commission approved a high dose regimen of SPINRAZA for 5q spinal muscular atrophy, supported by Phase 2/3 DEVOTE trial results and a prior approval in Japan.
See our latest analysis for Biogen.
These SPINRAZA developments and Biogen's conference presence come after a choppy stretch, with a 7 day share price return of 12.37% decline and a 1 year total shareholder return of 16.98%. This suggests that longer term holders have fared...